Skip to Content

Epirubicin Disease Interactions

There are 5 disease interactions with epirubicin:


Epirubicin (applies to epirubicin) heart disease/toxicity

Major Potential Hazard, Moderate plausibility. Applicable conditions: History - Myocardial Infarction

The use of epirubicin is contraindicated in patients with severe myocardial insufficiency, recent myocardial infarction, and severe arrhythmias. Myocardial toxicity, manifested in its most severe form by potentially fatal congestive heart failure (CHF), may occur either during therapy with epirubicin or months to years after termination of therapy. Risk factors may increase the risk of cardiac toxicity. Cardiac toxicity with epirubicin may occur at lower cumulative doses whether or not cardiac risk factors are present, so extreme caution is advised. Initial treatment with epirubicin should be preceded by a careful baseline assessment of cardiac function as measured by left ventricular ejection function (LVEF). Close cardiac monitoring during treatment is suggested.


Epirubicin (applies to epirubicin) liver disease

Major Potential Hazard, Moderate plausibility.

Patients with severe hepatic dysfunction should not be treated with epirubicin. The major route of elimination of epirubicin is the hepatobiliary system. Serum total bilirubin and AST levels should be evaluated before and during treatment with epirubicin. Patients with elevated bilirubin or AST may experience slower clearance of drug with an increase in overall toxicity. Lower doses are recommended in these patients.


Epirubicin (applies to epirubicin) neutropenia

Major Potential Hazard, Moderate plausibility.

Patients should not be treated with epirubicin if they have a baseline neutrophil count < 1500 cells/mm3. A dose-dependent, reversible leukopenia and/or neutropenia is the predominant manifestation of hematologic toxicity associated with epirubicin and represents the most common acute dose-limiting toxicity of this drug. Myelosuppression requires careful monitoring. Total and differential WBC, red blood cell (RBC), and platelet counts should be assessed before and during each cycle of therapy with epirubicin.


Epirubicin (applies to epirubicin) myelosuppression/infection

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Thrombocytopenia, Infection - Bacterial/Fungal/Protozoal/Viral

Before beginning treatment with epirubicin, patients should recover from any acute toxicities, such as stomatitis, neutropenia, thrombocytopenia, and generalized infections, of prior cytotoxic treatment.


Epirubicin (applies to epirubicin) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Serum creatinine should be assessed before and during therapy with epirubicin. Dosage adjustment is necessary in patients with serum creatinine >5 mg/dL. Patients undergoing dialysis have not been studied.

Epirubicin drug interactions

There are 537 drug interactions with epirubicin

Epirubicin alcohol/food interactions

There is 1 alcohol/food interaction with epirubicin

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.